All is not well with pharma and healthcare sector; know which stocks are in news!

Lupin, Aurobindo Pharma, Sun Pharma, SPARC and Dr Lal Pathlab are the stocks to keep an eye on. Let us see why!

BSE Healthcare sector has been underperforming the benchmark, with a loss of 7.87% in last one month while Sensex has lost 5.17%. While this week has seen a rebound in the sector after a long spell of sell-off, many companies in the sector are currently trading near their 52-week low levels.

Lupin, Aurobindo Pharma, Sun Pharma, SPARC and Dr Lal Pathlab are the stocks to keep an eye on. Let us see why!

Lupin last evening announced its results for the quarter and year ended on March 31, 2022. The company reported a net loss of Rs 511.89 crore compared to net profit of Rs 464.20 crore. While consolidated net revenue for Q4 grew marginally by 2.8% at Rs 3864.50 crore on a YoY basis, EBITA came in at Rs 226.45 crore down by 68% on YoY basis. The stock has tumbled 18% in last one month and on Monday logged a fresh 52-week low of Rs 672.80. In the morning session, the shares of Lupin are trading at Rs 626.75, a loss of 8.27% over its previous close.

Aurobindo Pharma informed in its exchange filing yesterday that it has received an establishment inspection report (EIR) from USFDA for Unit-5. A pre-approval inspection was carried out by US FDA during the period 8th to 15th February 2022. On completion of the inspection, Form 483 was issued with 5 observations. Based on the inspection review and the written responses provided by the company, the agency has concluded that the assessment is completed with 'no remaining deficiencies'. The shares hit a fresh 52-week low of Rs 534 on Tuesday taking last one month loss in share price to 21.58%. At the time of writing, shares of Aurobindo Pharma were trading at Rs 543.45, down by 2.86%.

Sun Pharma in a press release yesterday announced the launch of Brillo, a first-in-class oral lipid-lowering drug in India. It is a novel treatment option that will help manage high LDL cholesterol in patients with heart diseases, a condition which is growing at an alarming rate. At 10.20 am, it was trading at Rs 895.50 down 0.43%.

Sun Pharma Advanced Research (SPARC) announced its results for the quarter and year ended on March 31, 2022, on Tuesday. The company reported a net loss of Rs 71.05 crore compared to Net loss of Rs 56.72 crore. Net revenue for Q4 was down by 10.05%at Rs 25.24 crore on YoY basis, operating loss came in at Rs 66.54 crore compared to Rs 50.43 crore on YoY basis. At the time of writing, the shares of SPARC were trading at Rs 225.20 down 1.49 per cent.

Dr Lal Pathlabs announced its results for the quarter and year ended on March 31, 2022, on Tuesday. The company reported PAT of Rs 62.10 crore from Rs 85.10 crore showing degrowth of 27.03%. Net revenue for Q4 was up by 12.65 per cent at Rs 485.50 crore on YoY basis, EBITDA came in at Rs 121.10 crore was marginally lower by 0.74% on YoY basis. Post disappointing results, the shares logged a 52-week low of Rs 1954.30 in yesterday’s session. At the time of writing, the shares of Dr Lal Pathlabs were trading at Rs 1945 down 5.27%.